ArticleCancer discovery2015
Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer.
Article in Cancer discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 73 citations in OpenAlex.
- Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer.The Journal of clinical investigation · 2018Trial
- MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer.Cancer immunology research · 2026Article
- PET/CT-based quantification of intratumoral heterogeneity for predicting pathological complete response in breast cancer patients treated with neoadjuvant chemotherapy: A multicentre study.European journal of nuclear medicine and molecular imaging · 2026Article
- MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9bioRxiv : the preprint server for biology · 2026Article
- CXCR4Nature communications · 2025Article
- Prediction of axillary lymph node metastasis in T1 breast cancer using diffuse optical tomography, strain elastography and molecular markers.Quantitative imaging in medicine and surgery · 2025Article
- Sociobiology meets oncology: unraveling altruistic cooperation in cancer cells and its implications.Experimental & molecular medicine · 2025Review
- Dynamic altruistic cooperation within breast tumors.Molecular cancer · 2023Article
- The Role of Cancer Stem Cells and Their Extracellular Vesicles in the Modulation of the Antitumor Immunity.International journal of molecular sciences · 2022Review
- Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts.NPJ breast cancer · 2022Article
- Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies.Seminars in cancer biology · 2022Review
- Epithelial Stem Cells: Making, Shaping and Breaking the Niche.Advances in experimental medicine and biology · 2022Article
- Tumor-propagating side population cells are a dynamic subpopulation in undifferentiated pleomorphic sarcoma.JCI insight · 2021Article
- Review
- Heterogeneity within molecular subtypes of breast cancer.American journal of physiology. Cell physiology · 2021Review
- In Silico Logical Modelling to Uncover Cooperative Interactions in Cancer.International journal of molecular sciences · 2021Review
- Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.The Journal of clinical investigation · 2021Article
- Methodological Advancements for Investigating Intra-tumoral Heterogeneity in Breast Cancer at the Bench and Bedside.Journal of mammary gland biology and neoplasia · 2020Article
- Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.Molecular cancer · 2020Review
- ΔNp63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader-Follower Relationship That Drives Collective Invasion.Cancer research · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledIntratumoral heterogeneity correlates with clinical outcome and reflects the cellular complexity and dynamics within a tumor. Such heterogeneity is thought to contribute to radio- and chemoresistance because many treatments may target only certain tumor cell subpopulations. A better understanding of the functional interactions between various subpopulations of cells, therefore, may help in the development of effective cancer treatments. We identified a unique subpopulation of tumor cells expressing mesenchymal-like markers in a Trp53-null mouse model of basal-like breast cancer using fluorescence-activated cell sorting and microarray analysis. Both in vitro and in vivo experiments revealed the existence of cross-talk between these "mesenchymal-like" cells and tumor-initiating cells. Knockdown of genes encoding ligands upregulated in the mesenchymal cells and their corresponding receptors in the tumor-initiating cells resulted in reduced tumorigenicity and increased tumor latency. These studies illustrate the non-cell-autonomous properties and importance of cooperativity between tumor subpopulations. SIGNIFICANCE: Intratumoral heterogeneity has been considered one important factor in assessing a patient's initial response to treatment and selecting drug regimens to effectively increase tumor response rate. Elucidating the functional interactions between various subpopulations of tumor cells will help provide important new insights in understanding treatment response and tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.